News

Lower levels of pro-inflammatory immune signaling proteins were found in the blood of people with relapsing-remitting multiple sclerosis (RRMS) treated with Tysabri (natalizumab) and were associated with fewer relapses and less disability, a study has found.

Tecfidera (dimethyl fumarate) was detected in the breast milk of two women using the oral therapy to treat their multiple sclerosis, but at concentrations well below the “theoretical threshold of concern” for an infant, a case study reported. According to its investigators, this is the first…

An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive multiple sclerosis (MS) and very limited walking abilities. Patients reliant on wheelchairs or aids to walk even short distances generally have…

Early and continuous use of Ocrevus (ocrelizumab) significantly slows disability progression and delays the time until wheelchair reliance in people with primary progressive multiple sclerosis (PPMS), new Phase 3 data spanning more than six years show. Findings from the ORATORIO trial, comparing immediate use with a two-year delay, support Ocrevus’ sustained…

Typing patterns in daily smartphone use show clinically relevant changes over time in people with multiple sclerosis (MS), but not among healthy individuals, a study shows. Notably, these variations often coincided with clinically meaningful changes in measures of disease activity, disability, and/or fatigue in MS patients with and without…

Patients in the early stages of multiple sclerosis with mild to moderate symptoms of depression performed worse on cognitive tests related to multitasking than on those focused on single tasks, a study has found. Notably, no such association was observed among healthy individuals, suggesting an MS-related link between mood,…

The nonprofit Autoimmune Registry (ARI) has published its first comprehensive list of autoimmune diseases, with information addressing more than 150 disorders, their subtypes, and prevalence in the U.S. This list was created in part to provide patients and scientists easy access to the latest peer-reviewed research, information on clinical…

Progressive multiple sclerosis (MS) is the focus of the 2020 virtual European Multiple Sclerosis Platform (EMSP) annual meeting that runs though Friday, Nov. 20. Registration is free for the two-day conference. Those interested in participating can register here. According to a EMSP press release, topics to be discussed include the most…

A software platform, called CogniSoft, allows for automated assessments of cognitive health in people with multiple sclerosis (MS). The platform was described in the study “CogniSoft: A Platform for the Automation of Cognitive Assessment and Rehabilitation of Multiple Sclerosis,” published in the journal Computers. Cognitive impairment…

Marked differences in disease characteristics are observed between male and female patients with multiple sclerosis (MS) but they are more pronounced when comparing patients across clinical subtypes, a new study finds. The analysis found that although women are more prone to…

Using a small molecule called TEPP-46 to block the non-metabolic function of the enzyme pyruvate kinase M2 (PKM2) in T-helper (Th) immune cells did not lessen disease severity and redirected inflammation and neural damage from the spinal cord to the brain in a mouse model of multiple sclerosis…

Scientists have created myelin-producing cells, called oligodendrocytes, from pluripotent stem cells derived from patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) in just three weeks. They also demonstrated these lab-made oligodendrocytes were able to produce myelin — the fatty substance that normally wraps around neurons’…

The U.K.’s MS Trust has been awarded £50,000 (about $65,800) from the Coronavirus Community Support Fund — distributed by The National Lottery Community Fund — to further its “Supporting the MS community during Covid-19” project. Expected to run for six months, the project aims…

Note: This story was updated Aug. 17, 2021, to note that T.gondii infection is a risk factor for rheumatoid arthritis and lupus, not a protective factor.  Toxoplasmosis, an infection by the parasite Toxoplasma gondii, may confer a certain level of protection against multiple sclerosis (MS), according…

Start2Cure Foundation is funding a research project that will investigate the potential of a gene therapy approach to treat multiple sclerosis (MS). MS is an autoimmune disease characterized by the damage and loss of myelin — the protective layer around nerve fibers, or axons, that is crucial to the…

A bone marrow transplant may be particularly useful for those with relapsing forms of multiple sclerosis (MS) who, despite treatment with high-efficacy disease-modifying therapies (DMTs), continue to experience relapses or show signs of new lesions, experts say. According to new recommendations from the National Multiple Sclerosis Society,…

The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating event associated with multiple sclerosis (MS) can predict brain atrophy up to a decade later, a new study shows. Titled “Association of Serum Neurofilament Light Levels…

A non-invasive retina imaging technique known as optical coherence tomography (OCT) provided evidence of the neuroprotective effect of ibudilast (MN-166) — an oral medication designed to reduce the body’s inflammatory responses —  in people with progressive forms of multiple sclerosis (MS). The data also…

Exposure to air pollution, particularly to particulate matter 10 (PM10), small airborne and inhalable particles, may trigger inflammatory reactions in people with multiple sclerosis (MS), an Italian study reported. The study “Air pollution as a contributor to the inflammatory activity of multiple sclerosis” was published in the Journal of…

Immunic Therapeutics is seeking 60 more adults with relapsing-remitting multiple sclerosis (RRMS) to test a lower dose of IMU-838, its leading oral experimental therapy, in its ongoing Phase 2 EMPhASIS trial. The decision was based on previous trial results showing that both doses tested (30 and 45 mg…

The Israeli Innovation Authority has awarded Owlytics Healthcare a $1.3-million grant to support the company’s development of wearable artificial intelligence (AI) technology that has the potential to improve multiple sclerosis (MS) therapies and better evaluate treatment efficacy in clinical studies. The device would be able to continuously…

An autologous hematopoietic stem cell transplant (AHSCT) is more effective than Lemtrada (alemtuzumab) at achieving no evidence of disease activity and preventing relapses in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study in Sweden reported. Adverse events (side effects) were more frequent with AHSCT over the first three…

Treatment with Tysabri (natalizumab) was more effective than Gilenya (fingolimod) in helping people with relapsing–remitting multiple sclerosis (RRMS) achieve no evidence of disease activity, a head-to-head study suggested. The study, “BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS,” was…

The brain volume of people with relapsing-remitting multiple sclerosis (RRMS) undergoes a dynamic cycle of enlargement and contractions, a new study shows. Patients with a lower volume (contractions) had less severe MS and a shorter disease duration, the study found. Overall, these findings suggest that frequent monitoring of the…

The use of disease-modifying therapies (DMTs) in adults with multiple sclerosis (MS) increased the risk of precancerous growth in those older than 45 years of age, according to an age-related adverse events analysis of several dozen clinical trials. …

Extracellular vesicles (EVs), tiny sacs released from myelin-producing cells called oligodendrocytes, may help dampen the immune system’s attack against myelin, whose loss is the hallmark of multiple sclerosis (MS), a new mouse study shows. The findings suggest that oligodendrocytes-released EVs could work as an universal immunotherapy for MS…

Adults with active relapsing-remitting multiple sclerosis (RRMS) treated with Tysabri (natalizumab) had fewer new and accumulated lesions, and a lower relapse rate than those treated with Gilenya (fingolimod) for 24 weeks, according to…

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS). Sativex, by…

Using a two-pronged approach, researchers were able to restore myelin on regenerated nerve fibers in a mouse model of optic nerve injury, which has implications for multiple sclerosis (MS) and other diseases associated with myelin loss, a study reported. The study, “…

A $25,000 contest is inviting entrepreneurs who have multiple sclerosis (MS), or take care of someone with MS, to pitch their non-therapeutic solutions for people with the neurodegenerative disorder. The virtual Innovation Challenge, which takes place in March 2021, is part of a collaboration between patient-powered platform Lyfebulb…